Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Systemic Amyloidosis Mimicking Lung Cancer.

Fisch AS, Fintelmann FJ, Garcia-Moliner ML, Gaissert HA, Lennes I, Butera JN, Stone JR, Hariri LP.

Am J Respir Crit Care Med. 2019 Jul 26. doi: 10.1164/rccm.201812-2261IM. [Epub ahead of print] No abstract available.

PMID:
31348688
2.

Clonal haematopoiesis of indeterminate potential among cancer survivors exposed to myelotoxic chemotherapy.

Olszewski AJ, Chorzalska AD, Kim AS, Quesenberry PJ, Lopresti ML, Fenton MA, Reagan JL, Butera JN, Sahin I, Hamel C, Robison J, Petersen M, Dubielecka PM.

Br J Haematol. 2019 Aug;186(3):e31-e35. doi: 10.1111/bjh.15861. Epub 2019 Mar 11. No abstract available.

PMID:
30859554
3.

An in vitro acoustic analysis and comparison of popular stethoscopes.

Weiss D, Erie C, Butera J 3rd, Copt R, Yeaw G, Harpster M, Hughes J, Salem DN.

Med Devices (Auckl). 2019 Jan 15;12:41-52. doi: 10.2147/MDER.S186076. eCollection 2019.

4.

A new onset of thrombocytopenia and microangiopathic hemolytic anemia in the healthcare setting: A challenge for diagnosis.

Di M, Bian J, Butera JN.

Am J Hematol. 2019 Jan;94(1):145-148. doi: 10.1002/ajh.25298. Epub 2018 Nov 25. No abstract available.

PMID:
30264862
5.

Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease.

Ollila TA, Olszewski AJ, Butera JN, Quesenberry MI, Quesenberry PJ, Reagan JL.

Clin Lymphoma Myeloma Leuk. 2018 Mar;18(3):204-209. doi: 10.1016/j.clml.2018.01.007. Epub 2018 Jan 31.

PMID:
29433979
6.

Heterozygous Hemoglobin Sherwood Forest Causing Polycythemia.

Raghunathan VM, Butera JN, Treaba DO.

Case Rep Hematol. 2017;2017:8174207. doi: 10.1155/2017/8174207. Epub 2017 Sep 28.

7.

Low microchimeric cell density in tumors suggests alternative antineoplastic mechanism.

Jolis TW, Brucker BM, Schorl C, Butera JN, Quesenberry PJ.

Med Oncol. 2017 Apr;34(4):65. doi: 10.1007/s12032-017-0921-6. Epub 2017 Mar 22.

PMID:
28332165
8.

Therapies for Hemorrhagic Transformation in Acute Ischemic Stroke.

Stone JA, Willey JZ, Keyrouz S, Butera J, McTaggart RA, Cutting S, Silver B, Thompson B, Furie KL, Yaghi S.

Curr Treat Options Neurol. 2017 Jan;19(1):1. doi: 10.1007/s11940-017-0438-5. Review.

PMID:
28130682
9.

TAFRO Syndrome Associated with EBV and Successful Triple Therapy Treatment: Case Report and Review of the Literature.

Simons M, Apor E, Butera JN, Treaba DO.

Case Rep Hematol. 2016;2016:4703608. Epub 2016 Sep 29.

10.

Cryoglobulinemic membranoproliferative glomerulonephritis associated with mucosa-associated lymphoid tissue lymphoma treated with rituximab.

Ha AY, Noronha N, Gleason P, Winkler JN, Butera JN, Henriksen KJ, Hu SL.

Clin Nephrol Case Stud. 2016 Jan 19;4:1-4. doi: 10.5414/CNCS108740. eCollection 2016.

11.

Nonengraftment donor lymphocyte infusions for refractory acute myeloid leukemia.

Reagan JL, Fast LD, Nevola M, Mantripragada K, Mulder A, Claas FH, Rosati K, Schumacher A, Safran H, Young CT, Quesenberry MI, Winer ES, Butera JN, Quesenberry PJ.

Blood Cancer J. 2015 Dec 4;5:e371. doi: 10.1038/bcj.2015.100. No abstract available.

12.

Genetics and diffuse large B-Cell lymphoma.

Niroula R, Butera J.

R I Med J (2013). 2015 Nov 2;98(11):23-6.

PMID:
26517251
13.
14.

An innovation for improving maternal, newborn and child health (MNCH) service delivery in Jigawa State, northern Nigeria: a qualitative study of stakeholders' perceptions about clinical mentoring.

Okereke E, Tukur J, Aminu A, Butera J, Mohammed B, Tanko M, Yisa I, Obonyo B, Egboh M.

BMC Health Serv Res. 2015 Feb 15;15:64. doi: 10.1186/s12913-015-0724-4.

15.

Identification of antipsychotic drug fluspirilene as a potential p53-MDM2 inhibitor: a combined computational and experimental study.

Patil SP, Pacitti MF, Gilroy KS, Ruggiero JC, Griffin JD, Butera JJ, Notarfrancesco JM, Tran S, Stoddart JW.

J Comput Aided Mol Des. 2015 Feb;29(2):155-63. doi: 10.1007/s10822-014-9811-6. Epub 2014 Nov 7.

PMID:
25377899
16.

Differences in the clinical course of heparin induced thrombocytopenia before and after the availability of HIT IgG class testing.

Reagan JL, Ingham RR 2nd, Dalia S, Butera JN, Sweeney JD.

Thromb Res. 2014 Jul;134(1):90-2. doi: 10.1016/j.thromres.2014.04.030. Epub 2014 May 2.

PMID:
24830900
17.

Impact of electronic chemotherapy order forms on prescribing errors at an urban medical center: results from an interrupted time-series analysis.

Elsaid K, Truong T, Monckeberg M, McCarthy H, Butera J, Collins C.

Int J Qual Health Care. 2013 Dec;25(6):656-63. doi: 10.1093/intqhc/mzt067. Epub 2013 Oct 16.

PMID:
24132956
18.
19.

Cellular immunotherapy for refractory hematological malignancies.

Reagan JL, Fast LD, Safran H, Nevola M, Winer ES, Castillo JJ, Butera JN, Quesenberry MI, Young CT, Quesenberry PJ.

J Transl Med. 2013 Jun 19;11:150. doi: 10.1186/1479-5876-11-150.

20.

Similar outcomes in Asian and Western patients with diffuse large B-cell lymphoma treated with R-CHOP.

Castillo JJ, Sinclair N, Beltrán BE, Song MK, Ilic I, Leppa S, Nurmi H, Seki R, Uccella S, Li JM, Treaba DO, Stachurski D, Butera JN.

Leuk Res. 2013 Apr;37(4):386-91. doi: 10.1016/j.leukres.2013.01.002. Epub 2013 Jan 24.

PMID:
23352640
21.

Spontaneous regression of chronic lymphocytic leukemia to a monoclonal B-lymphocytosis or to a normal phenotype.

Nakhla PS, Butera JN, Treaba DO, Castillo JJ, Quesenberry PJ.

Leuk Lymphoma. 2013 Aug;54(8):1647-51. doi: 10.3109/10428194.2012.753449. Epub 2013 Jan 2. Review.

PMID:
23185961
22.

Prognosis in primary effusion lymphoma is associated with the number of body cavities involved.

Castillo JJ, Shum H, Lahijani M, Winer ES, Butera JN.

Leuk Lymphoma. 2012 Dec;53(12):2378-82. doi: 10.3109/10428194.2012.694075. Epub 2012 Jun 13.

PMID:
22591071
23.

Nonengraftment haploidentical cellular therapy for hematologic malignancies.

Reagan JL, Fast LD, Winer ES, Safran H, Butera JN, Quesenberry PJ.

Adv Hematol. 2012;2012:784213. doi: 10.1155/2012/784213. Epub 2012 Jan 18.

24.

The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP.

Castillo JJ, Beltran BE, Song MK, Ilic I, Leppa S, Nurmi H, Seki R, Uccella S, Li JM, Treaba DO, Stachurski D, Butera JN.

Leuk Res. 2012 Apr;36(4):413-7. doi: 10.1016/j.leukres.2011.12.012. Epub 2012 Jan 24.

PMID:
22277681
25.

EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru.

Beltran BE, Castillo JJ, Morales D, de Mendoza FH, Quinones P, Miranda RN, Gallo A, Lopez-Ilasaca M, Butera JN, Sotomayor EM.

Am J Hematol. 2011 Aug;86(8):663-7. doi: 10.1002/ajh.22078.

26.

Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL.

Reagan JL, Rosmarin A, Butera JN, Nadeem A, Schiffman FJ, Sikov WM, Winer E, Mega AE.

Cancer Chemother Pharmacol. 2011 Oct;68(4):1075-80. doi: 10.1007/s00280-011-1702-0. Epub 2011 Jul 15.

PMID:
21761371
27.

HIV-negative plasmablastic lymphoma: not in the mouth.

Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, Colvin GA, Butera JN.

Clin Lymphoma Myeloma Leuk. 2011 Apr;11(2):185-9. doi: 10.1016/j.clml.2011.03.008. Epub 2011 Apr 8. Review.

PMID:
21575922
28.

Emergency canine surgery in a deployed forward surgical team: a case report.

Beitler AL, Jeanette JP, McGraw AL, Butera JR, Vanfosson CA, Seery JM.

Mil Med. 2011 Apr;176(4):477-80.

PMID:
21539175
29.

The metabotropic glutamate receptor 7 allosteric modulator AMN082: a monoaminergic agent in disguise?

Sukoff Rizzo SJ, Leonard SK, Gilbert A, Dollings P, Smith DL, Zhang MY, Di L, Platt BJ, Neal S, Dwyer JM, Bender CN, Zhang J, Lock T, Kowal D, Kramer A, Randall A, Huselton C, Vishwanathan K, Tse SY, Butera J, Ring RH, Rosenzweig-Lipson S, Hughes ZA, Dunlop J.

J Pharmacol Exp Ther. 2011 Jul;338(1):345-52. doi: 10.1124/jpet.110.177378. Epub 2011 Apr 20.

PMID:
21508084
30.

Hematopoietic SCT for adult T-cell leukemia/lymphoma: a review.

Jabbour M, Tuncer H, Castillo J, Butera J, Roy T, Pojani J, Al-Malki M, Al-Homsi AS.

Bone Marrow Transplant. 2011 Aug;46(8):1039-44. doi: 10.1038/bmt.2011.27. Epub 2011 Feb 28. Review.

PMID:
21358685
31.

Acute myeloid leukemia in the elderly.

Ho C, Butera JN.

Med Health R I. 2011 Jan;94(1):7-9. No abstract available.

PMID:
21290987
32.

Epstein-barr virus-positive diffuse large B-cell lymphoma of the elderly: what we know so far.

Castillo JJ, Beltran BE, Miranda RN, Paydas S, Winer ES, Butera JN.

Oncologist. 2011;16(1):87-96. doi: 10.1634/theoncologist.2010-0213. Epub 2011 Jan 6. Review.

33.

Complete remission in two cases of adult T-cell leukemia/lymphoma treated with hyper-CVAD: a case report and review of the literature.

Alduaij A, Butera JN, Treaba D, Castillo J.

Clin Lymphoma Myeloma Leuk. 2010 Dec;10(6):480-3. doi: 10.3816/CLML.2010.n.084. Review.

PMID:
21156467
34.

Perioperative management of chronic anticoagulation in orthopaedic surgery.

Thakur NA, Czerwein JK, Butera JN, Palumbo MA.

J Am Acad Orthop Surg. 2010 Dec;18(12):729-38. Review.

PMID:
21119139
35.

Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma.

Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, Colvin G, Butera JN.

Leuk Lymphoma. 2010 Nov;51(11):2047-53. doi: 10.3109/10428194.2010.516040. Epub 2010 Oct 4.

PMID:
20919850
36.

Ion channel screening plates: design, construction, and maintenance.

Mayer SC, Butera JA, Diller DJ, Dunlop J, Ellingboe J, Fan KY, Kaftan E, Mekonnen B, Mobilio D, Paslay J, Tawa G, Vasilyev D, Bowlby MR.

Assay Drug Dev Technol. 2010 Aug;8(4):504-11. doi: 10.1089/adt.2009.0239.

PMID:
20470241
37.

Who wants to work in a rural health post? The role of intrinsic motivation, rural background and faith-based institutions in Ethiopia and Rwanda.

Serneels P, Montalvo JG, Pettersson G, Lievens T, Butera JD, Kidanu A.

Bull World Health Organ. 2010 May;88(5):342-9. doi: 10.2471/BLT.09.072728.

38.

Identification of pyridazino[4,5-b]indolizines as selective PDE4B inhibitors.

Donnell AF, Dollings PJ, Butera JA, Dietrich AJ, Lipinski KK, Ghavami A, Hirst WD.

Bioorg Med Chem Lett. 2010 Apr 1;20(7):2163-7. doi: 10.1016/j.bmcl.2010.02.044. Epub 2010 Feb 13.

PMID:
20202838
39.

Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma.

Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, Colvin G, Butera JN.

Oncologist. 2010;15(3):293-9. doi: 10.1634/theoncologist.2009-0304. Epub 2010 Feb 18.

40.

Preclinical characterization of BRL 44408: antidepressant- and analgesic-like activity through selective alpha2A-adrenoceptor antagonism.

Dwyer JM, Platt BJ, Rizzo SJ, Pulicicchio CM, Wantuch C, Zhang MY, Cummons T, Leventhal L, Bender CN, Zhang J, Kowal D, Lu S, Rajarao SJ, Smith DL, Shilling AD, Wang J, Butera J, Resnick L, Rosenzweig-Lipson S, Schechter LE, Beyer CE.

Int J Neuropsychopharmacol. 2010 Oct;13(9):1193-205. doi: 10.1017/S1461145709991088. Epub 2010 Jan 5.

PMID:
20047711
41.

Epstein-Barr virus as a prognostic factor in de novo nodal diffuse large B-cell lymphoma.

Morales D, Beltran B, De Mendoza FH, Riva L, Yabar A, Quiñones P, Butera JN, Castillo J.

Leuk Lymphoma. 2010 Jan;51(1):66-72. doi: 10.3109/10428190903308015.

PMID:
19860616
42.

Update on myelodysplastic syndrome.

Ho CM, Butera JN.

Med Health R I. 2009 Sep;92(9):315-7. No abstract available.

PMID:
19842531
43.

GAP-134 ([2S,4R]-1-[2-aminoacetyl]4-benzamidopyrrolidine-2-carboxylic acid) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs.

Hennan JK, Swillo RE, Morgan GA, Rossman EI, Kantrowitz J, Butera J, Petersen JS, Gardell SJ, Vlasuk GP.

J Cardiovasc Pharmacol Ther. 2009 Sep;14(3):207-14. doi: 10.1177/1074248409340779.

PMID:
19721133
44.

Are we training our fellows adequately in delivering bad news to patients? A survey of hematology/oncology program directors.

Hebert HD, Butera JN, Castillo J, Mega AE.

J Palliat Med. 2009 Dec;12(12):1119-24. doi: 10.1089/jpm.2009.0074.

PMID:
19698025
45.

Discovery of a class of potent gap-junction modifiers as novel antiarrhythmic agents.

Piatnitski Chekler EL, Butera JA, Di L, Swillo RE, Morgan GA, Rossman EI, Huselton C, Larsen BD, Hennan JK.

Bioorg Med Chem Lett. 2009 Aug 15;19(16):4551-4. doi: 10.1016/j.bmcl.2009.07.014. Epub 2009 Jul 9.

PMID:
19616941
46.

Acute myelogenous leukemia.

Shipley JL, Butera JN.

Exp Hematol. 2009 Jun;37(6):649-58. doi: 10.1016/j.exphem.2009.04.002. Review.

PMID:
19463767
47.

Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).

Lovering F, Kirincich S, Wang W, Combs K, Resnick L, Sabalski JE, Butera J, Liu J, Parris K, Telliez JB.

Bioorg Med Chem. 2009 May 1;17(9):3342-51. doi: 10.1016/j.bmc.2009.03.041. Epub 2009 Mar 26.

PMID:
19364658
48.

The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model.

Rossman EI, Liu K, Morgan GA, Swillo RE, Krueger JA, Gardell SJ, Butera J, Gruver M, Kantrowitz J, Feldman HS, Petersen JS, Haugan K, Hennan JK.

J Pharmacol Exp Ther. 2009 Jun;329(3):1127-33. doi: 10.1124/jpet.108.150102. Epub 2009 Feb 27.

PMID:
19252062
49.

An interesting fishing expedition.

Quesenberry PJ, Butera JN.

Cancer Biol Ther. 2009 Feb;8(4):338-9. Epub 2009 Feb 12. No abstract available.

PMID:
19197147
50.

Discovery of (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride (GAP-134)13, an orally active small molecule gap-junction modifier for the treatment of atrial fibrillation.

Butera JA, Larsen BD, Hennan JK, Kerns E, Di L, Alimardanov A, Swillo RE, Morgan GA, Liu K, Wang Q, Rossman EI, Unwalla R, McDonald L, Huselton C, Petersen JS.

J Med Chem. 2009 Feb 26;52(4):908-11. doi: 10.1021/jm801558d.

PMID:
19175320

Supplemental Content

Loading ...
Support Center